Back to mobile site

Celcuity (CELC) Reiterated at Buy by Stifel on Revtorpyk Approval

July 15, 2026 7:22 AM EDT Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $175.00 price target on Celcuity Inc (NASDAQ: CELC).The analyst commented, "FDA’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login